AAV-mediated delivery of enzymes, neurotransmitter-modulating proteins, or neurotrophic factors has been extensively explored in Parkinson’s disease. While early studies suggested biological activity, several randomized controlled trials failed to meet primary clinical endpoints, highlighting the challenges of placebo effects, target engagement, and disease heterogeneity.